With R&D flops mounting, Eli Lilly likely to slash budget, analysts say

The litany of clinical trial failures for Eli Lilly's ($LLY) pipeline programs is likely to force the company to start carving up its R&D budget as the pharma giant enters a 7-year drought on the sales side, according to a group of analysts tracked by the Indianapolis Business Journal. Report